Effects of novel glucose-lowering drugs on the lipid parameters: A systematic review and meta-analysis

We aim to evaluate the impacts of sodium-glucose co-transporter 2 inhibitors (SGLT-2), glucagon-like peptide 1 agonist (GLP-1RAs), and dipeptidyl peptidase-four (DPP4) inhibitors on the levels of high-density lipoprotein, low-density lipoprotein, triglyceride and total cholesterol. The MEDLINE datab...

Full description

Saved in:
Bibliographic Details
Published in:Annals of medicine and surgery 2022-05, Vol.77, p.103633-103633, Article 103633
Main Authors: Dar, Sophia, Siddiqi, Ahmed Kamal, Alabduladhem, Tamim Omar, Rashid, Ahmed Mustafa, Sarfraz, Saba, Maniya, Talha, Menezes, Ritesh G., Almas, Talal
Format: Article
Language:English
Subjects:
DPP-4 inhibitors
GLP-1 agonist
Lipid parameters
Meta-analysis
SGLT2 inhibitors
Systematic Review / Meta-analysis
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We aim to evaluate the impacts of sodium-glucose co-transporter 2 inhibitors (SGLT-2), glucagon-like peptide 1 agonist (GLP-1RAs), and dipeptidyl peptidase-four (DPP4) inhibitors on the levels of high-density lipoprotein, low-density lipoprotein, triglyceride and total cholesterol. The MEDLINE database was searched from inception till October 2021, for randomized controlled trials assessing the effects of sodium-glucose co-transporter two inhibitors (SGLT-2), glucagon-like peptide 1 agonist (GLP-1RAs), and dipeptidyl peptidase-four (DPP4) inhibitors on lipid levels. A total of 57 trials were included in the analysis. Our pooled analysis demonstrates that SGLT-2 inhibitors significantly increase the levels of HDL (WMD = 0.07 mg/dL [0.06 to 0.08], P 
ISSN:2049-0801
2049-0801
DOI:10.1016/j.amsu.2022.103633